UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
Jair Bar(Tel Aviv University), Alfredo Addeo, Estelamari Rodríguez(University of Miami), Nir Peled(Shaare Zedek Medical Center), Giulio Metro(University of Perugia), Yakir Rottenberg(Hadassah Medical Center), Frank Aboubakar Nana(Cliniques Universitaires Saint-Luc), Martin Reck(German Center for Lung Research), Alona Zer(Rambam Health Care Campus), Waleed Kian(Soroka Medical Center), Christoforos Astaras(Hôpital Beau-Séjour), Sandip Pravin Patel(University of California San Diego), Hadas Gantz-Sorotsky(Tel Aviv University), Shiruyeh Schokrpur(National Foundation for Cancer Research), Kristof Cuppens(Jessa Hospital), Sofie Derijcke(AZ Groeninge), Dror Limon(Tel Aviv Sourasky Medical Center), Nicolas Girard(Institut Curie), Antonio Calles(Dana-Farber Cancer Institute), Adrienne Bettini(Fribourg Development Agency), Lynn Decoster(AZ Turnhout), Mirjana Wolner(Rambam Health Care Campus), Simon Häfliger(University of Bern), Ofer Rotem(Rabin Medical Center), Mor Moskovitz(Rambam Health Care Campus), Maximilian J. Hochmair(Karl Landsteiner Society)
Cited by 97
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k